Interestingly, this compound is lethal against AML expressing MLL-rearrangements and, interestingly, also NMP1 mutation (64), suggesting that use of this compound may be extended beyond the spectrum of MLL-rearranged AMLs. Here, KMT2A is linked to acute myeloid leukemia.